Use of Enoxaparin in Patients with Chronic Kidney Disease
- 110 Downloads
The authors have no conflicts of interest that are directly relevant to the content of this commentary. No sources of funding were used to assist in the preparation of this commentary.
- 2.United States Renal Data Systems (USRDS). 2006 annual data report: atlas of chronic kidney disease and end stage renal disease in the United States. Chapter 6: Morbidity and mortality. Am J Kidney Dis 2007; 49 (1 Suppl.): S130–46994Google Scholar
- 4.Cohen M, Demers C, Gurfinkle EP, et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. Am J Cardiol 1998; 82(5B): 19L–24LPubMedCrossRefGoogle Scholar
- 8.Lovenox® (enoxaparin sodium) [package insert]. Bridgewater (NJ): Sanofi-Aventis Pharmaceuticals, 2007 JunGoogle Scholar
© Adis Data Information BV 2007